- Conditions
- Corneal Epithelial Disorders
- Interventions
- High Dose SJP-0035 Ophthalmic Solution, Low Dose SJP-0035 Ophthalmic Solution, Vehicle of SJP-0035 Ophthalmic solution
- Drug
- Lead sponsor
- Senju Pharmaceutical Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 19
- States / cities
- Little Rock, Arkansas • Glendora, California • Lancaster, California + 16 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 1,356
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain Tumor
- Interventions
- Not listed
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Bacterial Conjunctivitis
- Interventions
- Auriclosene Solution 0.3%, Auriclosene Vehicle
- Drug
- Lead sponsor
- NovaBay Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year and older
- Enrollment
- 217 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 18 more
- Conditions
- Healthy
- Interventions
- PF-04634817
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Infantile Hemangiomas
- Interventions
- Timolol 0.5% Gel Forming Solution (GFS), Mupirocin 2% Ointment
- Drug
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Month to 8 Months
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Cystic Fibrosis
- Interventions
- TOBIpodhaler
- Drug
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetic Retinopathy
- Interventions
- OTT166, Vehicle control
- Drug
- Lead sponsor
- OcuTerra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 67
- States / cities
- Peoria, Arizona • Phoenix, Arizona • Beverly Hills, California + 59 more
- Conditions
- Mydriasis
- Interventions
- Tropicamide/Phenylephrine ophthalmic solution (TR/PE), Placebo
- Drug
- Lead sponsor
- Eyenovia Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 76 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Austin, Texas • San Antonio, Texas
- Conditions
- Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma
- Interventions
- 1. Drug: The Venetoclax PK study is collecting bodily fluid samples (ie., whole blood and optional cerebrospinal fluid) of patients prescribed venetoclax as crushed tablets per standard of care.
- Other
- Lead sponsor
- Children's Hospital Medical Center, Cincinnati
- Other
- Eligibility
- 0 Years to 38 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Aurora, Colorado • Atlanta, Georgia • Cincinnati, Ohio + 3 more
- Conditions
- Ocular Surface Disease, Dry Eye Syndrome (DES)
- Interventions
- (Xiidra®) Lifitegrast Ophthalmic Solution 5.0%
- Drug
- Lead sponsor
- Pittsburgh Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- Sewickley, Pennsylvania
- Conditions
- Peri-implant Mucositis, Peri-Implantitis
- Interventions
- Induction of experimental peri-implant mucositis, Resolution of experimental peri-implant mucositis
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Diabetic Macular Edema
- Interventions
- SF0166 Topical Ophthalmic Solution
- Drug
- Lead sponsor
- OcuTerra Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 6
- States / cities
- Beverly Hills, California • Inglewood, California • Rancho Cordova, California + 3 more
- Conditions
- Rhematoid Arthritis, Osteo Arthritis of the Knee, Traumatic Arthritis of Knee (Diagnosis), Polyarthritis, Collagen Disorders, Avascular Necrosis of Femoral Condyle, Valgus Deformity, Varus Deformity, Flexion Deformity of Knee
- Interventions
- Total knee arthroplasty
- Device
- Lead sponsor
- Zimmer Biomet
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2037
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Louisville, Kentucky • Baltimore, Maryland
- Conditions
- General Population
- Interventions
- OptiBP Study app
- Device
- Lead sponsor
- Biospectal
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 500,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Truckee, California
- Conditions
- Anxiety, Depression, Posttraumatic Stress Disorder
- Interventions
- Cognitive Behavioral Therapy (CBT), CBT+App
- Behavioral
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 7 Years to 17 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Nosocomial Infections
- Interventions
- Talactoferrin, Placebo
- Drug
- Lead sponsor
- Agennix
- Industry
- Eligibility
- 1 Minute to 24 Hours
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Louisville, Kentucky • Columbia, Missouri
- Conditions
- Alzheimer Disease
- Interventions
- Zunveyl®
- Drug
- Lead sponsor
- Alpha Cognition, Inc
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 22
- States / cities
- Irvine, California • Orange, California • Aventura, Florida + 17 more
- Conditions
- Dry Eye Syndrome
- Interventions
- SkQ1 Vehicle Solution, SkQ1 Ophthalmic Solution
- Drug
- Lead sponsor
- Mitotech, SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 4
- States / cities
- Sun City West, Arizona • Andover, Massachusetts • San Antonio, Texas + 1 more
- Conditions
- Skin Diseases, Infectious
- Interventions
- sterile Phosphate Buffer Saline, SGW13
- Other
- Lead sponsor
- Center for Innovation and Research Organization
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Opioid-Related Disorders
- Interventions
- Buprenorphine formulation: liquid vs. tablet
- Drug
- Lead sponsor
- National Institute on Drug Abuse (NIDA)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 1999
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alcohol Use Disorder
- Interventions
- Acamprosate calcium, Placebo
- Drug · Other
- Lead sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- NIH
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Neovascular Age Related Macular Degeneration
- Interventions
- OCT, Multifocal ERG, Microperimetry, Ranibizumab Ophthalmic
- Device · Drug
- Lead sponsor
- Retina Macula Institute
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Torrance, California
- Conditions
- Viral Infection
- Interventions
- UV-4B 3 mg, UV-4B 10 mg, UV-4B 30 mg, UV-4B 90 mg, UV-4B 180 mg, UV-4B 360 mg, UV-4B 720 mg, UV-4B 1000 mg, Placebo
- Drug
- Lead sponsor
- Emergent BioSolutions
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy
- Interventions
- tofacitinib modified release (MR)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut